Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
A roundup of the first quarter's key oncology drug approvals and rejections.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
